BEDFORD, Mass.--(BUSINESS WIRE)--Jan. 7, 2020--
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company
pioneering a new way to treat the underlying cause of severe genetic
diseases by precisely upregulating protein expression, today
announced that Chief Executive Officer Edward M. Kaye, M.D., will
present at the 38th Annual J.P. Morgan Healthcare Conference
on Tuesday, January 14, 2020 at 2:30 p.m. PT (5:30 p.m. ET) in San
Francisco.
A live audio webcast of the presentation will be available on the
Investors & Media section of Stoke’s website at https://investor.stoketherapeutics.com/.
A replay of the webcast will be available for 30 days following the
presentations.
About Stoke Therapeutics
Stoke Therapeutics,
Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to
treat the underlying causes of severe genetic diseases by precisely
upregulating protein expression to restore target proteins to near
normal levels. Stoke aims to develop the first precision medicine
platform to target the underlying cause of a broad spectrum of genetic
diseases in which the patient has one healthy copy of a gene and one
mutated copy that fails to produce a protein essential to health. These
diseases, in which loss of approximately 50% of normal protein
expression causes disease, are called autosomal dominant
haploinsufficiencies. The company’s lead investigational new medicine is
STK-001, a proprietary antisense oligonucleotide (ASO) that has the
potential to be the first disease-modifying therapy to address the
genetic cause of Dravet syndrome, a severe and progressive genetic
epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices
in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or
follow the company on Twitter at @StokeTx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005163/en/
Source: Stoke Therapeutics, Inc.
Stoke Media & Investor Contact:
Dawn Kalmar
Vice
President, Head of Corporate Affairs
dkalmar@stoketherapeutics.com
781-303-8302